Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease
Abstract SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options a...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2019-04, Vol.58 (4), p.567-579 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 579 |
|---|---|
| container_issue | 4 |
| container_start_page | 567 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 58 |
| creator | Khanna, Dinesh Tashkin, Donald P Denton, Christopher P Lubell, Martin W Vazquez-Mateo, Cristina Wax, Stephen |
| description | Abstract
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell-cell and cell-extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD. |
| doi_str_mv | 10.1093/rheumatology/key151 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6434373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/key151</oup_id><sourcerecordid>2054929909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-dcc8ee9c310585c68e3e3335b945cb5f38d652e1aae954d25b9bf5b9431c67613</originalsourceid><addsrcrecordid>eNqNUU1v1DAQtRCItgu_AAlZ4sIlrT_ibHxBQhVQpEq9wNnyOpNdF8cOHqfV_ntctqwKJ04zmvfmzccj5A1n55xpeZF3sEy2pJC2-4sfsOeKPyOnvO1Ew6QUz4-5aE_IGeItY0xx2b8kJ0L3WmrZn5L7m7hNPm6pCz56ZwMt2duA1MahpmDLBLHQNBefItIxZTrb4msN6b0vO4p7LDB5R9EFyAk9NhYxOW8LDNTHAhmLL1WThqXOGTyCRXhFXox1DLx-jCvy_fOnb5dXzfXNl6-XH68b165FaQbnegDtJGeqV67rQYKUUm10q9xGjbIfOiWAWwtatYOowGZ8QCV33brjckU-HHTnZTPB4Ori2QYzZz_ZvDfJevM3Ev3ObNOd6VrZyrWsAu8fBXL6uQAWM3l0EIKNkBY0gqlWC62rIyvy7h_qbVpyrOcZIVmnWqF-s-SB5eq3MMN4XIYz82CseWqsORhbu94-vePY88fJSjg_ENIy_5fiLxtyuL4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2306542509</pqid></control><display><type>article</type><title>Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Khanna, Dinesh ; Tashkin, Donald P ; Denton, Christopher P ; Lubell, Martin W ; Vazquez-Mateo, Cristina ; Wax, Stephen</creator><creatorcontrib>Khanna, Dinesh ; Tashkin, Donald P ; Denton, Christopher P ; Lubell, Martin W ; Vazquez-Mateo, Cristina ; Wax, Stephen</creatorcontrib><description>Abstract
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell-cell and cell-extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/key151</identifier><identifier>PMID: 29893938</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Clinical trials ; Clinical Trials as Topic ; Humans ; Immunologic Factors - therapeutic use ; Inflammation ; Inhibitor drugs ; Lung diseases ; Lung Diseases, Interstitial - drug therapy ; Lung Diseases, Interstitial - etiology ; Lymphocytes ; Morbidity ; Patients ; Pulmonary fibrosis ; Quality of life ; Respiratory function ; Reviews ; Scleroderma ; Scleroderma, Systemic - complications ; Systemic sclerosis ; Toxicity</subject><ispartof>Rheumatology (Oxford, England), 2019-04, Vol.58 (4), p.567-579</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2018</rights><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-dcc8ee9c310585c68e3e3335b945cb5f38d652e1aae954d25b9bf5b9431c67613</citedby><cites>FETCH-LOGICAL-c472t-dcc8ee9c310585c68e3e3335b945cb5f38d652e1aae954d25b9bf5b9431c67613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29893938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khanna, Dinesh</creatorcontrib><creatorcontrib>Tashkin, Donald P</creatorcontrib><creatorcontrib>Denton, Christopher P</creatorcontrib><creatorcontrib>Lubell, Martin W</creatorcontrib><creatorcontrib>Vazquez-Mateo, Cristina</creatorcontrib><creatorcontrib>Wax, Stephen</creatorcontrib><title>Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Abstract
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell-cell and cell-extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD.</description><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Inflammation</subject><subject>Inhibitor drugs</subject><subject>Lung diseases</subject><subject>Lung Diseases, Interstitial - drug therapy</subject><subject>Lung Diseases, Interstitial - etiology</subject><subject>Lymphocytes</subject><subject>Morbidity</subject><subject>Patients</subject><subject>Pulmonary fibrosis</subject><subject>Quality of life</subject><subject>Respiratory function</subject><subject>Reviews</subject><subject>Scleroderma</subject><subject>Scleroderma, Systemic - complications</subject><subject>Systemic sclerosis</subject><subject>Toxicity</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqNUU1v1DAQtRCItgu_AAlZ4sIlrT_ibHxBQhVQpEq9wNnyOpNdF8cOHqfV_ntctqwKJ04zmvfmzccj5A1n55xpeZF3sEy2pJC2-4sfsOeKPyOnvO1Ew6QUz4-5aE_IGeItY0xx2b8kJ0L3WmrZn5L7m7hNPm6pCz56ZwMt2duA1MahpmDLBLHQNBefItIxZTrb4msN6b0vO4p7LDB5R9EFyAk9NhYxOW8LDNTHAhmLL1WThqXOGTyCRXhFXox1DLx-jCvy_fOnb5dXzfXNl6-XH68b165FaQbnegDtJGeqV67rQYKUUm10q9xGjbIfOiWAWwtatYOowGZ8QCV33brjckU-HHTnZTPB4Ori2QYzZz_ZvDfJevM3Ev3ObNOd6VrZyrWsAu8fBXL6uQAWM3l0EIKNkBY0gqlWC62rIyvy7h_qbVpyrOcZIVmnWqF-s-SB5eq3MMN4XIYz82CseWqsORhbu94-vePY88fJSjg_ENIy_5fiLxtyuL4</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Khanna, Dinesh</creator><creator>Tashkin, Donald P</creator><creator>Denton, Christopher P</creator><creator>Lubell, Martin W</creator><creator>Vazquez-Mateo, Cristina</creator><creator>Wax, Stephen</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190401</creationdate><title>Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease</title><author>Khanna, Dinesh ; Tashkin, Donald P ; Denton, Christopher P ; Lubell, Martin W ; Vazquez-Mateo, Cristina ; Wax, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-dcc8ee9c310585c68e3e3335b945cb5f38d652e1aae954d25b9bf5b9431c67613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Inflammation</topic><topic>Inhibitor drugs</topic><topic>Lung diseases</topic><topic>Lung Diseases, Interstitial - drug therapy</topic><topic>Lung Diseases, Interstitial - etiology</topic><topic>Lymphocytes</topic><topic>Morbidity</topic><topic>Patients</topic><topic>Pulmonary fibrosis</topic><topic>Quality of life</topic><topic>Respiratory function</topic><topic>Reviews</topic><topic>Scleroderma</topic><topic>Scleroderma, Systemic - complications</topic><topic>Systemic sclerosis</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khanna, Dinesh</creatorcontrib><creatorcontrib>Tashkin, Donald P</creatorcontrib><creatorcontrib>Denton, Christopher P</creatorcontrib><creatorcontrib>Lubell, Martin W</creatorcontrib><creatorcontrib>Vazquez-Mateo, Cristina</creatorcontrib><creatorcontrib>Wax, Stephen</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khanna, Dinesh</au><au>Tashkin, Donald P</au><au>Denton, Christopher P</au><au>Lubell, Martin W</au><au>Vazquez-Mateo, Cristina</au><au>Wax, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>58</volume><issue>4</issue><spage>567</spage><epage>579</epage><pages>567-579</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Abstract
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell-cell and cell-extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>29893938</pmid><doi>10.1093/rheumatology/key151</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2019-04, Vol.58 (4), p.567-579 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6434373 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Clinical trials Clinical Trials as Topic Humans Immunologic Factors - therapeutic use Inflammation Inhibitor drugs Lung diseases Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Lymphocytes Morbidity Patients Pulmonary fibrosis Quality of life Respiratory function Reviews Scleroderma Scleroderma, Systemic - complications Systemic sclerosis Toxicity |
| title | Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A40%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ongoing%20clinical%20trials%20and%20treatment%20options%20for%20patients%20with%20systemic%20sclerosis-associated%20interstitial%20lung%20disease&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Khanna,%20Dinesh&rft.date=2019-04-01&rft.volume=58&rft.issue=4&rft.spage=567&rft.epage=579&rft.pages=567-579&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/key151&rft_dat=%3Cproquest_pubme%3E2054929909%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2306542509&rft_id=info:pmid/29893938&rft_oup_id=10.1093/rheumatology/key151&rfr_iscdi=true |